AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05867550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
Study NCT04933084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Opioid Education
Description: The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction.
Study NCT05896722 — intervention group
Intervention type: OTHER
Intervention: Core muscle endurance
Description: Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
Study NCT05896722 — intervention group
Intervention type: OTHER
Intervention: Upper extremity muscle strength
Description: Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
Study NCT05896722 — intervention group
Intervention type: OTHER
Intervention: Grip strength
Description: Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
Study NCT05896722 — intervention group
Intervention type: OTHER
Intervention: Pinch strength
Description: Pinch strength will be evaluated with a pinchmeter in three positions.
Study NCT05896722 — intervention group
Intervention type: OTHER
Intervention: Alternate hand-wall toss test
Description: To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
Study NCT04388904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Description: Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
Study NCT05207917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
Study NCT05207917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
Study NCT05207917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve ileal (SASI) bypass
Description: The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
Study NCT05565443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier Disruption - Functional
Description: Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
Study NCT05867550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebeverine 135 MG
Description: Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
Study NCT01609439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 800 units for 4 weeks preoperatively
Study NCT01609439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05725408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy-informed group eating intervention protocol (telehealth)
Description: A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
Study NCT05725408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical behavior therapy-informed group eating intervention protocol (in-person)
Description: A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
Study NCT05591612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt replacement seasoning (50% salt and 50% MSG) mix
Description: Individuals in this group were provided a seasoning that replaced 50 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 50/50 MSG Mix to be added to vegetables in diet.
Study NCT05591612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt replacement seasoning (70% salt and 30% MSG) mix
Description: Individuals in this group were provided a seasoning that replaced 30 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 70/30 MSG Mix to be added to vegetables in diet.
Study NCT05591612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NaCl (sodium chloride/table salt)
Description: Individuals in this group were asked to use normal seasoning of regular salt. This study assessed the vegetable intake using table salt to be added to vegetables in diet.
Study NCT05867550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium Husk
Description: Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
Study NCT05867550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline Hydrochloride 25 MG
Description: Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
Study NCT06478225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT007H Cell Injection
Description: Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28).
Study NCT04105946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
Study NCT04105946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: remifentanil administration intraoperatively in combination with other drugs used in TIVA
Study NCT06304805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 1: treatment drug
Description: for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study NCT05901415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position
Description: We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
Study NCT05901415 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.
Description: Patients posed in a classical position and received combined anterior LPB and lateral SPB.
Study NCT05330741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designed Physical Therapy Program
Description: The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.
Study NCT05330741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration
Description: The designed physical therapy program (mentioned before)~+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively.
Study NCT05330741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gravity Force Stimulation
Description: The designed physical therapy program (mentioned before)~+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)
Study NCT06304805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 1: reference drug
Description: for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Study NCT06304805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycle 1: fasted
Description: for cycle 1 treatment: participants are asked to take the drug fasted
Study NCT06304805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycle 1: food
Description: for cycle 1 treatment: participants are asked to take the drug after food intake
Study NCT06304805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 2: treatment drug
Description: for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study NCT06304805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 2: reference drug
Description: for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Study NCT06304805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycle 2: fasted
Description: for cycle 2 treatment: participants are asked to take the drug fasted
Study NCT06304805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycle 2: food
Description: for cycle 2 treatment: participants are asked to take the drug after food intake
Study NCT06304805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 3: treatment drug
Description: for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
Study NCT06304805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cycle 3: reference drug
Description: for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
Study NCT06304805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycle 3: fasted
Description: for cycle 3 treatment: participants are asked to take the drug fasted
Study NCT06304805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycle 3: food
Description: for cycle 3 treatment: participants are asked to take the drug after food intake
Study NCT04747067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOPURE 260HF dialyzer
Description: Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
Study NCT05755607 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic pancreaticoduodenectomy
Description: The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
Study NCT05755607 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robot Pancreaticoduodenectomy
Description: The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
Study NCT05484154 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion
Study NCT05484154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
Study NCT05922319 — intervention group
Intervention type: OTHER
Intervention: Computerized cognitive training with different training doses
Description: The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.
Study NCT04892628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
Study NCT04892628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic training
Description: The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
Study NCT05234879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame Running
Description: Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
Study NCT04878432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Solution for intravenous infusion
Study NCT04878432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Solution for subcutaneous injection or intravenous infusion
Study NCT04878432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Solution for intravenous infusion
Study NCT04878432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INQOVI (oral decitabine)
Description: Tablet for oral administration
Study NCT05269888 — intervention group
Intervention type: OTHER
Intervention: Blood Test 1
Description: Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres
Study NCT06469411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)
Description: Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks
Study NCT06469411 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4 cc distilled water dissolved in albumin 20%
Description: Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
Study NCT05269888 — intervention group
Intervention type: OTHER
Intervention: Blood Test 2
Description: Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres
Study NCT04913337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study NCT04913337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM707 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
Study NCT05581498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, Bike exercise and muscle strength exercise.
Description: Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks.
Study NCT05581498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Bike exercise and muscle strength exercise.
Description: Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks.
Study NCT05960227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran
Description: Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
Study NCT05960227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250ml of saline 0,9% for 4 hours insusion.
Study NCT05766488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: A continuous glucose monitor will be provided in the experimental arm of this study for 6 months. This monitor will be a Freestyle Libre 2 device.
Study NCT05766488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional glucometer
Description: A traditional glucometer device will be assigned in the standard of care arm of this study for 6 months.
Study NCT05129293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective Memory Intervention
Description: Cognitive remediation focusing on prospective memory
Study NCT05129293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational
Description: Psychoeducation